Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Summit Therapeu ADR (NQ: SMMT ) 9.980 UNCHANGED Streaming Delayed Price Updated: 4:00 PM EDT, Jul 24, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 0 Open 9.980 Bid (Size) 9.900 (1) Ask (Size) 10.50 (10) Prev. Close 9.980 Today's Range 9.980 - 9.980 52wk Range 1.520 - 11.25 Shares Outstanding 97,381,774 Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Stock Market News For July 23: Quick Takes On GE Aerospace, Boeing, Biotechs July 23, 2024 What sectors outperformed after Trump won the 2016 election, and which outperformed during his term? Via Investor's Business Daily Topics Government Exposures Political IQVIA Posts Upbeat Earnings, Joins Terex, Reddit And Other Big Stocks Moving Higher On Monday July 22, 2024 Via Benzinga Performance YTD +278.03% +278.03% 1 Month +24.75% +24.75% 3 Month +177.99% +177.99% 6 Month +125.28% +125.28% 1 Year +396.52% +396.52% More News Read More XPeng & QuantumScape Are Among Top 11 Mid Cap Stocks That Performed Well Last Week (July 7-July 13): Details July 14, 2024 Via Benzinga Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) July 03, 2024 From Summit Therapeutics Inc. Via Business Wire 7 Top Stocks Under $10: June 2024 Edition June 24, 2024 Via InvestorPlace 3 Stocks That Have Soared 179% or More in 2024 and Could Go Even Higher, According to Wall Street June 17, 2024 Via The Motley Fool Week In Review: Structure Reports Efficacy Of Obesity Drug; Raises $476 Million June 08, 2024 Via Talk Markets 10 Health Care Stocks With Whale Alerts In Today's Session June 07, 2024 Via Benzinga Five Below Posts Weak Q1 Results, Joins Sprinklr, Dorian LPG And Other Big Stocks Moving Lower In Thursday's Pre-Market Session June 06, 2024 Via Benzinga Why Summit Therapeutics Stock Is Trading 8% Higher Monday June 03, 2024 Via Benzinga Stericycle, MarineMax, Agios Pharmaceuticals And Other Big Stocks Moving Higher On Monday June 03, 2024 Via Benzinga Summit Raises $200 Million; Also Expands License Territories for Ivonescimab June 03, 2024 From Summit Therapeutics Inc. Via Business Wire Day Trading During A Slow Holiday Week June 01, 2024 Via Talk Markets Week In Review: MediLink And BioNTech Form $1.8 Billion ADC Partnership June 01, 2024 Via Talk Markets Ivonescimab Manuscript for HARMONi-A Clinical Trial Results Published in JAMA June 01, 2024 From Summit Therapeutics Inc. Via Business Wire Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for 2L+ EGFRm NSCLC based on HARMONi-A Clinical Trial: Positive Trend Observed in Overall Survival towards Ivonescimab Plus Chemotherapy May 31, 2024 From Summit Therapeutics Inc. Via Business Wire Why SentinelOne Shares Are Trading Lower By 16%? Here Are Other Stocks Moving In Friday's Mid-Day Session May 31, 2024 Via Benzinga 12 Health Care Stocks Moving In Friday's Intraday Session May 31, 2024 Via Benzinga Summit Therapeutics' Lung Cancer Therapy Ivonescimab Shows Improved Progression-Free Survival Versus Merck's Multi-Billion Keytruda In China Study May 31, 2024 Via Benzinga 12 Health Care Stocks Moving In Friday's Pre-Market Session May 31, 2024 Via Benzinga Why Zscaler Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket May 31, 2024 Via Benzinga Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday May 31, 2024 Via InvestorPlace Marvell Technology Posts Weak Q1 Results, Joins MongoDB, Dell Technologies And Other Big Stocks Moving Lower In Friday's Pre-Market Session May 31, 2024 Via Benzinga Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) May 30, 2024 From Summit Therapeutics Inc. Via Business Wire Ivonescimab Monotherapy Decisively Beats Pembrolizumab Monotherapy Head-to-Head, Achieves Statistically Significant Superiority in PFS in First-Line Treatment of Patients with PD-L1 Positive NSCLC in China May 30, 2024 From Summit Therapeutics Inc. Via Business Wire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
